Enhancing self-esteem in people with multiple sclerosis using the Lexical Association Technique
Official title: Améliorer l'Estime de Soi Des Patients Atteints de sclérose en Plaques : Test d'efficacité de la Technique d'Association Lexicale
Run by University Hospital, Grenoble · NCT07064291 · Data updated 2026-11-12
This trial tests whether the Lexical Association Technique can improve well-being and quality of life for adults with recent MS diagnoses compared with a placebo-like control.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 1 site (Grenoble) |
| Status | Recruiting |
| Started | January 28, 2026 |
| Main results expected | July 27, 2027 |
| Study ends | July 27, 2027 |
| Registry record updated | October 2, 2026 |
| Trial ID | NCT07064291 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with relapsing-remitting or secondary progressive MS diagnosed within the last 1–5 years, native French speakers, and with home computer and internet access on first- or second-line oral therapy.
✕Probably not a fit
Patients without access to a computer or internet, non-French speakers, or those outside the 1–5 year onset window may obtain little or no benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized trial compares the Lexical Association Technique (LAT) to an active control in adults with relapsing-remitting or secondary progressive MS diagnosed within the past 1–5 years. Participants complete at-home visualization exercises and fill out validated questionnaires on self-esteem, stress, anxiety, depression, quality of life, and adjustment to illness across multiple study points. The study uses computer-based intervention delivery and assesses immediate and short-term effects, with follow-up 14 days after the intervention. Enrollment requires native French speakers with at-home internet access, on first- or second-line oral MS therapy. Primary goals are to see if LAT increases well-being more than the control and whether it reduces psychological distress and improves quality of life.
Why it matters
Potential benefit: If successful, LAT could provide a non-pharmacologic option to boost self-esteem and overall well-being in people with MS.
How similar studies have gone: Prior work suggests psychosocial approaches can improve quality of life and well-being in MS, but the specific LAT approach is novel in this context.
Who can join: the full rules
Show full inclusion / exclusion criteria
INCLUSION CRITERIA * Native French speaker * Access to a computer and internet connection at home * Diagnosis of multiple sclerosis according to the revised criteria of Thompson et al. (2018), either relapsing-remitting or secondary progressive form, between 1 and 5 years since disease onset (RRMS or SPMS entry phase) * Currently receiving first- or second-line oral treatment (e.g., Teriflunomide, Dimethylfumarate, Fingolimod, Cladribine) * Adult participants (age ≥ 18) NON-INCLUSION CRITERIA * Participant currently excluded from another study * Individuals covered by Articles L1121-5 to L1121-8 of the French Public Health Code (CSP), i.e., legally protected persons: pregnant women, women in labor, breastfeeding mothers, individuals deprived of liberty by judicial or administrative decision, individuals under psychiatric care under Articles L.3212-1 and L.3213-1 not falling under Article L.1121-8, individuals admitted to healthcare or social institutions for reasons other than research, minors, individuals under legal protection or unable to provide informed consent * Staff members with a hierarchical link to the principal investigator SECONDARY EXCLUSION CRITERIA * Participants not presenting with low self-esteem, i.e., score \>26 on the Self-Esteem Scale (EES; Vallières \& Vallerand, 1990) * Major life event significantly affecting well-being in the two weeks prior to study inclusion (e.g., bereavement, separation, childbirth, etc.) * Initiation of psychological, psychiatric, or pharmacological treatment (anxiolytics, antidepressants) within one month prior to study start
Where it's running
-
CHU Grenoble Alpes
Grenoble, France Recruiting
Study contacts
- Principal investigator: Mathieu VAILLANT — CHU Grenoble Alpes, France
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Tolebrutinib in real-world MS care for patients treated by clinicians
This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.
-
Pilates via live video vs. prerecorded videos for people with multiple sclerosis
This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.
-
Cooling During Inpatient Rehab for People with MS
This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.